Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 10/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1799829 | 0.97 | AVPR1B (0.41) | AVPR1BALKKDM4EALDH1A1LMNA | |
| SCHEMBL1795337 | 0.95 | AVPR1B (0.42) | AVPR1BALKKDM4EALDH1A1LMNA | |
| SCHEMBL1795051 | 0.95 | AVPR1B (0.42) | AVPR1BALKKDM4EALDH1A1LMNA | |
| SCHEMBL1796879 | 0.94 | AVPR1B (0.49) | AVPR1BKDM4EALDH1A1 | |
| SCHEMBL1795105 | 0.94 | AVPR1B (0.41) | AVPR1BALKKDM4EALDH1A1LMNA | |
| SCHEMBL1796883 | 0.93 | AVPR1B (0.48) | AVPR1BALK | |
| SCHEMBL1796113 | 0.93 | AVPR1B (0.39) | AVPR1BKDM4EALDH1A1LMNAHTT | |
| SCHEMBL1797590 | 0.93 | AVPR1B (0.40) | AVPR1BALKKDM4EALDH1A1LMNA | |
| SCHEMBL1796069 | 0.92 | ALDH1A1 (0.43) | AVPR1BKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1466069 | 0.92 | AVPR1B (0.39) | AVPR1BALKMGLLSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338590-B2 | Substituted oxindole derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | ABBOTT GMBH & CO. KG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-7951807-B2 | Substituted oxindol derivatives and medicaments containing the same | ABBOTT GMBH & CO. KG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005397-A1 | Substituted Oxindol Derivatives and Medicaments Containing the Same | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885ALK 4873/4885KDM4E 4081/4885 |
| US-20110257194-A1 | SUBSTITUTED OXINDOL DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885ALK 4851/4885KDM4E 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.